Markowitz J S, Wells B G, Carson W H
Department of Hospital Pharmacy Practice and Administration, Medical University of South Carolina, USA.
Ann Pharmacother. 1995 Jun;29(6):603-9. doi: 10.1177/106002809502900610.
To provide a comprehensive review of the pharmacokinetic and pharmacodynamic interactions between antipsychotics and antihypertensive and to provide recommendations for the selection of antihypertensive in patients receiving antipsychotic therapy.
A MEDLINE search of the English-language literature was used to identify pertinent human and animal studies, reviews, and case reports.
All available sources were reviewed.
Background information was obtained from comprehensive reviews. Individual case reports were assimilated, and pertinent data were extracted.
Because hypertension is common in patients with psychiatric illness and antihypertensive agents are used for a multiplicity of indications, significant numbers of patients receive concurrent therapy with antihypertensives and antipsychotics. Many antipsychotics may block the antihypertensive efficacy of guanethidine and related drugs. The interaction between clonidine and antipsychotics is defined less clearly. Limited data suggest possible additive hypotensive effects when chlorpromazine and methyldopa are given in combination. Increased plasma concentrations of thioridazine with a resultant increase in adverse effects have been reported when propranolol or pindolol are added to the regimen. A similar increase in chlorpromazine concentrations has been reported when propranolol was added. Although there are no reports documenting an interaction between a calcium-channel antagonist and an antipsychotic, the possible inhibition of oxidative metabolism of antipsychotics, additive calcium-blocking activity, and additive pharmacodynamic effects are theorized. Hypotension and postural syncope were reported in a patient given therapeutic dosages of chlorpromazine and captopril, and in 2 patients when clozapine was added to enalapril therapy.
No antipsychotic-antihypertensive combination is absolutely contraindicated, but no combination should be considered to be completely without risk. Antihypertensives with no centrally acting activity, such as diuretics, may be the least likely to result in adverse reactions. The combination of the beta-antagonists propranolol or pindolol with thioridazine or chlorpromazine should be avoided if possible. Scrupulous patient monitoring for attenuated or enhanced activity of either agent is essential whenever antipsychotics and antihypertensives are given concurrently.
全面综述抗精神病药物与抗高血压药物之间的药代动力学和药效学相互作用,并为接受抗精神病治疗的患者选择抗高血压药物提供建议。
通过检索MEDLINE英文文献,以识别相关的人体和动物研究、综述及病例报告。
对所有可得资料进行了综述。
背景信息来自全面综述。整理了个别病例报告并提取了相关数据。
由于高血压在精神疾病患者中很常见,且抗高血压药物有多种适应证,大量患者同时接受抗高血压药物和抗精神病药物治疗。许多抗精神病药物可能会阻断胍乙啶及相关药物的降压效果。可乐定与抗精神病药物之间的相互作用尚不太明确。有限的数据表明,氯丙嗪和甲基多巴联用时可能有相加的降压作用。有报道称,在治疗方案中加用普萘洛尔或吲哚洛尔后,硫利达嗪的血浆浓度升高,不良反应随之增加。加用普萘洛尔后,氯丙嗪浓度也有类似升高。虽然尚无文献记录钙通道拮抗剂与抗精神病药物之间的相互作用,但理论上存在抗精神病药物氧化代谢受抑制、相加的钙阻滞活性及相加的药效学效应的可能。有1例患者在接受治疗剂量的氯丙嗪和卡托普利时出现低血压和体位性晕厥,另有2例患者在依那普利治疗中加用氯氮平后出现同样情况。
没有哪种抗精神病药物与抗高血压药物的组合是绝对禁忌的,但也没有哪种组合可被认为完全没有风险。无中枢作用的抗高血压药物,如利尿剂,引发不良反应的可能性可能最小。应尽可能避免β受体拮抗剂普萘洛尔或吲哚洛尔与硫利达嗪或氯丙嗪联用。无论何时同时给予抗精神病药物和抗高血压药物,都必须严密监测患者,以观察两种药物的活性是减弱还是增强。